ORIC Pharmaceuticals (Nasdaq: ORIC) increases inducement equity share pool
Rhea-AI Filing Summary
ORIC Pharmaceuticals amended and restated its 2022 Inducement Equity Incentive Plan, effective July 28, 2026, to increase the shares of common stock reserved for issuance under the plan by 1,100,000, to 3,350,000 shares in total, subject to the plan’s adjustment provisions.
The Inducement Plan, adopted without stockholder approval under applicable Nasdaq Listing Rules, permits various equity awards, including options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance stock units. Awards may be granted only as inducement awards to new employees after a bona fide break in service, or, where permitted, in connection with a merger or acquisition.
Positive
- None.
Negative
- None.
Filing Explained
Effective July 28, ORIC’s plan amendment adds 1,100,000 shares to the pool reserved for equity awards, raising the total to 3,350,000; it creates issuance capacity rather than reporting an issuance, so any resulting reduction in existing holders’ percentage ownership depends on later awards and share issuance.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Additional shares reserved under Inducement Plan: 1,100,000 shares
Aggregate shares reserved under Inducement Plan: 3,350,000 shares
Effective date of amended Inducement Plan: July 28, 2026
3 metrics
Additional shares reserved under Inducement Plan
1,100,000 shares
Increase in share pool approved effective July 28, 2026
Aggregate shares reserved under Inducement Plan
3,350,000 shares
Total shares available for awards after the amendment
Effective date of amended Inducement Plan
July 28, 2026
Date the Board approved the amended and restated plan
Key Terms
Inducement Plan, Nasdaq Listing Rules, stock appreciation rights, change in control
4 terms
Inducement Plan financial
"approved the ORIC Pharmaceuticals, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
Nasdaq Listing Rules regulatory
"The Inducement Plan and increases to the shares reserved thereunder were adopted without stockholder approval pursuant to the applicable Nasdaq Listing Rules"
Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.
stock appreciation rights financial
"including nonstatutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance stock units"
Stock appreciation rights (SARs) are a form of employee compensation that give the holder the right to receive the increase in a company's stock price over a set baseline, paid in cash or shares, without having to buy the stock. For investors, SARs matter because they can create future cash outflows or share dilution and signal how a company rewards and motivates executives — similar to giving a bonus tied directly to how well the company’s stock performs.
change in control financial
"treatment of equity awards in the event of a “merger” or “change in control” as defined under the Inducement Plan"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did ORIC (ORIC) change in its 2022 Inducement Equity Incentive Plan?
ORIC amended and restated its 2022 Inducement Equity Incentive Plan to expand the share pool. The Board added 1,100,000 shares, bringing the total reserved for inducement awards to 3,350,000 shares of common stock, subject to the plan’s adjustment provisions.
Who is eligible to receive awards under ORIC’s amended Inducement Plan (ORIC)?
Awards under ORIC’s Inducement Plan may be granted only to individuals who were not previously employees or non-employee directors, or following a bona fide period of non-employment, as an inducement to join, or, where Nasdaq rules allow, in connection with a merger or acquisition.
Did ORIC (ORIC) obtain stockholder approval for the amended Inducement Plan?
The amended Inducement Plan and its increased share reserve were adopted without stockholder approval. ORIC relied on the applicable Nasdaq Listing Rules, which permit inducement and certain acquisition-related equity awards without a shareholder vote when specific conditions are met.
What types of equity awards can ORIC (ORIC) grant under the Inducement Plan?
The Inducement Plan allows a range of equity-based awards, including nonstatutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance stock units, with terms generally similar to ORIC’s 2020 Equity Incentive Plan.
When did ORIC’s (ORIC) amended Inducement Plan become effective?
The Board made the Amended and Restated 2022 Inducement Equity Incentive Plan effective on July 28, 2026. From that date, the increased share reserve of 3,350,000 shares became available for qualifying inducement and certain acquisition-related equity awards.